{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:35:14Z","timestamp":1792787714932,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1245\/s10434-021-10147-2","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T20:02:23Z","timestamp":1621108943000},"page":"4772-4774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intraperitoneal EpCAM-Targeted Immunotoxin: A First Step Towards Engineering the Immune Environment in Colorectal Peritoneal Metastases?"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-4419","authenticated-orcid":false,"given":"Wim","family":"Ceelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"10147_CR1","doi-asserted-by":"publisher","unstructured":"Thorgersen EB, Asvall J, Fr\u00f8ysnes IS, et al. Increased local inflammatory response to MOC31PE immunotoxin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2021. https:\/\/doi.org\/10.1245\/s10434-021-10022-0.","DOI":"10.1245\/s10434-021-10022-0"},{"issue":"1","key":"10147_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","volume":"109","author":"JS Kim","year":"2020","unstructured":"Kim JS, Jun SY, Kim YS. Critical issues in the development of immunotoxins for anticancer therapy. J Pharm Sci. 2020;109(1):104\u201315.","journal-title":"J Pharm Sci."},{"issue":"2","key":"10147_CR3","doi-asserted-by":"publisher","first-page":"188436","DOI":"10.1016\/j.bbcan.2020.188436","volume":"1874","author":"F Fagotto","year":"2020","unstructured":"Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration, and potential impact on invasion: a critical review. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188436.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"3","key":"10147_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","volume":"39","author":"O Gires","year":"2020","unstructured":"Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev. 2020;39(3):969\u201387.","journal-title":"Cancer Metastasis Rev."},{"issue":"11","key":"10147_CR5","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/bjc.2015.380","volume":"113","author":"Y Andersson","year":"2015","unstructured":"Andersson Y, Engebraaten O, Juell S, et al. Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. Br J Cancer. 2015;113(11):1548\u201355.","journal-title":"Br J Cancer."},{"issue":"4","key":"10147_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/0284186X.2019.1704864","volume":"59","author":"Y Andersson","year":"2020","unstructured":"Andersson Y, Inderberg EM, Kvalheim G, et al. Immune stimulatory effect of anti-EpCAM immunotoxin\u2014improved overall survival of metastatic colorectal cancer patients. Acta Oncol. 2020;59(4):404\u20139.","journal-title":"Acta Oncol."},{"issue":"7","key":"10147_CR7","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1245\/s10434-017-5814-6","volume":"24","author":"IS Fr\u00f8ysnes","year":"2017","unstructured":"Fr\u00f8ysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa phase 1 trial. Ann Surg Oncol. 2017;24(7):1916\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"10147_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejso.2019.04.014","volume":"47","author":"IS Fr\u00f8ysnes","year":"2021","unstructured":"Fr\u00f8ysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. Eur J Surg Oncol. 2021;47(1):134\u20138.","journal-title":"Eur J Surg Oncol."},{"issue":"8","key":"10147_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","volume":"5","author":"Y Leshem","year":"2017","unstructured":"Leshem Y, O\u2019Brien J, Liu X, et al. Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity. Cancer Immunol Res. 2017;5(8):685\u201394.","journal-title":"Cancer Immunol Res."},{"issue":"1","key":"10147_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"10147_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","volume":"6","author":"W Ceelen","year":"2020","unstructured":"Ceelen W, Ramsay RG, Narasimhan V, Heriot AG, De Wever O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 2020;6(3):236\u201346.","journal-title":"Trends Cancer."},{"issue":"13","key":"10147_CR12","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1245\/s10434-020-08870-3","volume":"27","author":"J Franko","year":"2020","unstructured":"Franko J, Brahmbhatt R, Tee M, et al. Cellular immunoprofile of peritoneal environment during a HIPEC procedure. Ann Surg Oncol. 2020;27(13):5005\u201313.","journal-title":"Ann Surg Oncol."},{"key":"10147_CR13","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/ncomms14754","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.","journal-title":"Nat Commun."},{"issue":"3","key":"10147_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/vaccines6030054","volume":"6","author":"A Thadi","year":"2018","unstructured":"Thadi A, Khalili M, Morano WF, Richard SD, Katz SC, Bowne WB. Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis. Vaccines (Basel). 2018;6(3):54.","journal-title":"Vaccines (Basel)."},{"issue":"3","key":"10147_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000324667","volume":"34","author":"MA Str\u00f6hlein","year":"2011","unstructured":"Str\u00f6hlein MA, Lordick F, R\u00fcttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I\/II trial. Onkologie. 2011;34(3):101\u20138.","journal-title":"Onkologie."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10147-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10147-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10147-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T20:18:35Z","timestamp":1628367515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10147-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10147"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10147-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}